Helius Medical Technologies, Inc. (Nasdaq: HSDT) has announced that CignaHealth has authorized claims for payment of the ...

CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of ...

Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced that Aetna Healthcare has authorized a claim for reimbursement for ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of ...

CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers ...

A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, ...

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be $9.1 million. The offering is expected to close on June 6, 2025, subject to the ...

market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process ...

Marketed as a safer alternative to traditional e-cigarettes, these high-tech devices may actually expose users to harmful metals found in both the liquid and the vapor they produce. U-cigarettes use a ...

Assistive devices (and related technologies known as “adaptive equipment”) help us perform many of our daily tasks with less pain, improve our level of independence, and allow us to preserve the ...